{"title":"Parallel evolutionary trajectories of extensively drug-resistant <i>Klebsiella pneumoniae</i> ST258 and ST307 pandemic clones: a systematic review.","authors":"Sampurna Nivedita Sarkar, Surojit Das","doi":"10.1139/cjm-2025-0268","DOIUrl":null,"url":null,"abstract":"<p><p>Extensively drug-resistant (XDR) <i>Klebsiella pneumoniae</i> poses a critical threat to global public health. ST258 and ST307 are two pandemic clones that have emerged through distinct evolutionary mechanisms. Understanding their parallel trajectories is essential for clinical management and therapeutic development. This systematic review examined peer-reviewed literature on <i>K. pneumoniae</i> ST258 and ST307 (1995-2025) from PubMed, Scopus, Google Scholar, and Web of Science. We extracted data on resistance genes, virulence factors, geographic distribution, and clinical outcomes. Inclusion criteria: studies with molecular or genomic characterization of ST258/ST307 isolates. Analysis revealed distinct evolutionary pathways. ST258 (emerged 1995, USA) showed recombination driven evolution with stable <i>bla</i><sub>KPC-2/3</sub> resistance, remaining hospital-endemic and declining after 2015. ST307 (emerged 2008, Netherlands) demonstrated plasmid-mediated adaptability with diverse carbapenemases (<i>bla</i><sub>NDM</sub>, <i>bla</i><sub>OXA-48</sub>, <i>bla</i><sub>KPC</sub>), achieving rapid global dissemination across six WHO regions by 2025. Both achieved pandemic status through different mechanisms. ST307 shows emerging hypervirulent sublineages in Europe and South America. Two distinct evolutionary strategies converge to create a unified pandemic threat. ST258's stability contrasts with ST307's adaptability, reflecting different fitness landscapes. Both clones exhibit limited susceptibility to current therapeutic options, with emerging resistance to last-resort agents. ST258 and ST307 represent complementary pandemic threats requiring coordinated global surveillance, antimicrobial development, and research into evolutionary dynamics.</p>","PeriodicalId":9381,"journal":{"name":"Canadian journal of microbiology","volume":" ","pages":"1-12"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1139/cjm-2025-0268","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Extensively drug-resistant (XDR) Klebsiella pneumoniae poses a critical threat to global public health. ST258 and ST307 are two pandemic clones that have emerged through distinct evolutionary mechanisms. Understanding their parallel trajectories is essential for clinical management and therapeutic development. This systematic review examined peer-reviewed literature on K. pneumoniae ST258 and ST307 (1995-2025) from PubMed, Scopus, Google Scholar, and Web of Science. We extracted data on resistance genes, virulence factors, geographic distribution, and clinical outcomes. Inclusion criteria: studies with molecular or genomic characterization of ST258/ST307 isolates. Analysis revealed distinct evolutionary pathways. ST258 (emerged 1995, USA) showed recombination driven evolution with stable blaKPC-2/3 resistance, remaining hospital-endemic and declining after 2015. ST307 (emerged 2008, Netherlands) demonstrated plasmid-mediated adaptability with diverse carbapenemases (blaNDM, blaOXA-48, blaKPC), achieving rapid global dissemination across six WHO regions by 2025. Both achieved pandemic status through different mechanisms. ST307 shows emerging hypervirulent sublineages in Europe and South America. Two distinct evolutionary strategies converge to create a unified pandemic threat. ST258's stability contrasts with ST307's adaptability, reflecting different fitness landscapes. Both clones exhibit limited susceptibility to current therapeutic options, with emerging resistance to last-resort agents. ST258 and ST307 represent complementary pandemic threats requiring coordinated global surveillance, antimicrobial development, and research into evolutionary dynamics.
广泛耐药肺炎克雷伯菌对全球公共卫生构成严重威胁。ST258和ST307是通过不同的进化机制出现的两个大流行克隆。了解它们的平行轨迹对临床管理和治疗发展至关重要。本系统综述检查了PubMed、Scopus、谷歌Scholar和Web of Science上关于肺炎克雷伯菌ST258和ST307(1995-2025)的同行评议文献。我们提取了耐药基因、毒力因素、地理分布和临床结果的数据。纳入标准:具有ST258/ST307分离株分子或基因组特征的研究。分析揭示了不同的进化途径。ST258(1995年出现于美国)表现出重组驱动的进化,具有稳定的blaKPC-2/3耐药性,仍在医院流行,2015年后有所下降。ST307(2008年出现于荷兰)表现出质粒介导的对多种碳青霉烯酶(blaNDM、OXA、KPC)的适应性,到2025年在世卫组织六个区域迅速传播。两者通过不同的机制达到大流行的地位。ST307显示在欧洲和南美出现的高毒力亚系。两种截然不同的进化策略汇聚在一起,形成了统一的大流行威胁。ST258的稳定性与ST307的适应性形成对比,反映了不同的健身景观。这两个克隆体对目前的治疗方案都表现出有限的敏感性,对最后手段的药物出现了耐药性。ST258和ST307是互补的大流行威胁,需要协调的全球监测、抗菌药物开发和进化动力学研究。
期刊介绍:
Published since 1954, the Canadian Journal of Microbiology is a monthly journal that contains new research in the field of microbiology, including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.